Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression
Fibrate drug FNF exerts antitumor effects by targeting the mitochondrial complex I-AMPK/mTOR-CD276 axis, inducing mitochondrial dysfunction, and downregulating the immunosuppressive molecule CD276 to activate T cell-mediated antitumor immunity. This study provides a potential strategy for drug repurposing and identifies a novel target for immunotherapeutic combination strategies in bladder cancer.
Authors
- Jiahao Liu (ORCID: https://orcid.org/0000-0001-6239-1973)
- Wei Xiong (ORCID: https://orcid.org/0000-0002-3017-9895)
- Long Wang (ORCID: https://orcid.org/0000-0003-4583-2428)
- Li Cheng (ORCID: https://orcid.org/0000-0001-8984-0812)
Institutions
- Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1186/s12885-025-14855-w
- Citations
- 1
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Natural Science Foundation of China
- Central South University
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- Fundamental Research Funds for Central Universities of the Central South University